Literature DB >> 34901174

Scalp Psoriasis and Biologic Agents: A Review.

Ilias Papadimitriou1, Katerina Bakirtzi1, Alexander Katoulis2, Dimitrios Ioannides1.   

Abstract

Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis. Herein, we sought to evaluate the efficacy of biologics and small molecules in controlling the symptoms and their ability to offer long-term maintenance in the disease activity.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Biologics; Psoriasis; Review; Scalp psoriasis; Small molecules

Year:  2021        PMID: 34901174      PMCID: PMC8613563          DOI: 10.1159/000517806

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  40 in total

1.  Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.

Authors:  S Tyring; J Bagel; C Lynde; P Klekotka; E H Z Thompson; S R Gandra; Y Shi; G Kricorian
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-12-21       Impact factor: 6.166

2.  The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch.

Authors:  Leigh A Nattkemper; Hong Liang Tey; Rodrigo Valdes-Rodriguez; Helen Lee; Nicholas K Mollanazar; Christian Albornoz; Kristen M Sanders; Gil Yosipovitch
Journal:  J Invest Dermatol       Date:  2018-01-06       Impact factor: 8.551

3.  Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

Authors:  Kim A Papp; Andrew Blauvelt; Michael Bukhalo; Melinda Gooderham; James G Krueger; Jean-Philippe Lacour; Alan Menter; Sandra Philipp; Howard Sofen; Stephen Tyring; Beate R Berner; Sudha Visvanathan; Chandrasena Pamulapati; Nathan Bennett; Mary Flack; Paul Scholl; Steven J Padula
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

4.  Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.

Authors:  C Fotiadou; E Lazaridou; E Sotiriou; A Kyrgidis; Z Apalla; D Ioannides
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-07-13       Impact factor: 6.166

5.  Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.

Authors:  E Papadavid; D Ferra; D Koumaki; M Dalamaga; C Stamou; K Theodoropoulos; D Rigopoulos
Journal:  Dermatology       Date:  2014-02-01       Impact factor: 5.366

Review 6.  Itching for an answer: A review of potential mechanisms of scalp itch in psoriasis.

Authors:  Argentina Leon; Jordan D Rosen; Takashi Hashimoto; Anna C Fostini; Ralf Paus; Gil Yosipovitch
Journal:  Exp Dermatol       Date:  2019-05-15       Impact factor: 3.960

7.  Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.

Authors:  R G Langley; P Rich; A Menter; G Krueger; O Goldblum; Y Dutronc; B Zhu; H Wei; G S Cameron; M P Heffernan
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-02-18       Impact factor: 6.166

8.  Natural history and treatment of scalp psoriasis.

Authors:  E M Farber; L Nall
Journal:  Cutis       Date:  1992-06

9.  Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).

Authors:  Kristian Reich; Craig Leonardi; Mark Lebwohl; Francisco Kerdel; Yukari Okubo; Ricardo Romiti; Orin Goldblum; Ellen B Dennehy; Lisa Kerr; Howard Sofen
Journal:  J Dermatolog Treat       Date:  2016-11-13       Impact factor: 3.359

10.  Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation.

Authors:  C Stanley Chan; Abby S Van Voorhees; Mark G Lebwohl; Neil J Korman; Melodie Young; Bruce F Bebo; Robert E Kalb; Sylvia Hsu
Journal:  J Am Acad Dermatol       Date:  2009-04-17       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.